Celularity Inc. has entered into an exclusive manufacturing and commercial collaboration with Vesalius Longevity Labs Inc. to manufacture peptide active pharmaceutical ingredients (APIs) for Vesalius's Peptual® brand. This partnership leverages Celularity's existing U.S.-based manufacturing infrastructure to establish a domestic supply platform, creating a new revenue opportunity for the company.
Key Details
- Agreement: Celularity will serve as the exclusive partner for the final stage U.S. manufacturing of Vesalius's Peptual® peptide APIs.
- Celularity's Role: The company will perform downstream purification, processing, analytical testing, and manufacturing at its cGMP facility in Florham Park, New Jersey.
- Strategic Goal: The collaboration aims to create a resilient and traceable domestic supply chain for peptide APIs, addressing regulatory concerns about imported ingredients.
- Scope Exclusion: The agreement explicitly excludes the manufacturing of GLP-1 receptor agonists or other weight-loss peptides.